Literature DB >> 2230255

Prevalence of homozygous C4B deficiency in patients with deficiencies of terminal complement components and meningococcemia.

M B Fasano, P Densen, R H McLean, J A Winkelstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2230255     DOI： 10.1093/infdis/162.5.1220

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  6 in total

1.  Immunoglobulins and complement factor C4 in adult rhinosinusitis.

Authors:  M Seppänen; J Suvilehto; M-L Lokki; I-L Notkola; A Järvinen; H Jarva; I Seppälä; O Tahkokallio; H Malmberg; S Meri; V Valtonen
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

Review 2.  Infections of people with complement deficiencies and patients who have undergone splenectomy.

Authors:  Sanjay Ram; Lisa A Lewis; Peter A Rice
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 3.  Infectious diseases associated with complement deficiencies.

Authors:  J E Figueroa; P Densen
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

4.  Combined total deficiency of C7 and C4B with systemic lupus erythematosus (SLE).

Authors:  O G Segurado; A A Arnaiz-Villena; P Iglesias-Casarrubios; J Martinez-Laso; J L Vicario; G Fontan; M Lopez-Trascasa
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

5.  Target deletion of complement component 9 attenuates antibody-mediated hemolysis and lipopolysaccharide (LPS)-induced acute shock in mice.

Authors:  Xiaoyan Fu; Jiyu Ju; Zhijuan Lin; Weiling Xiao; Xiaofang Li; Baoxiang Zhuang; Tingting Zhang; Xiaojun Ma; Xiangyu Li; Chao Ma; Weiliang Su; Yuqi Wang; Xuebin Qin; Shujuan Liang
Journal:  Sci Rep       Date:  2016-07-22       Impact factor: 4.379

Review 6.  Human genetics of meningococcal infections.

Authors:  Stephanie Hodeib; Jethro A Herberg; Michael Levin; Vanessa Sancho-Shimizu
Journal:  Hum Genet       Date:  2020-02-17       Impact factor: 4.132
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.